In vitro leukocyte thymidine uptake and prognosis in chronic lymphocytic leukemia

Moayeri, H; Sokal, Joseph E.

doi:10.1016/0002-9343(79)91115-x

Cited by 25 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The remaining patient with TKl isoenzyme status has had a splenectomy and the disease has been partially controlled for 25 months with intermittent chlorambucil and prednisolone therapy. A change from a clinically indolent to aggressive disease is a well-documented occurrence for chronic lymphocytic leukaemia and has been associated with the appearance of immature lymphocytes in the peripheral blood (Enno et al, 1979) and enhanced in uitro leucocyte thymidine uptake (Moayeri & Sokal, 1979). The detection of peripheral blood lymphocyte TK1 isoenzyme activity in this study is consistent with this reported cytological immaturity and enhanced spontaneous thymidine uptake.…”

Section: Resultssupporting

confidence: 87%

Thymidine Kinase Isoenzymes in Chronic Lymphocytic Leukaemia

1981

View full text Add to dashboard Cite

The profile of thymidine kinase isoenzymes was determined in peripheral blood lymphocytes from 14 patients with chronic lymphocytic leukaemia (CLL) and 31 controls. Twelve patients with indolent disease showed TK2 isoenzyme activity, while two patients in whom the disease evolved and two patients who presented with aggressive disease exhibited TK1 isoenzyme activity. The demonstration of TK1 activity in the peripheral blood lymphocytes of clinically aggressive CLL suggests that this isoenzyme may be a useful biochemical marker of such behaviour.

show abstract

Section: Resultssupporting

confidence: 87%

Thymidine Kinase Isoenzymes in Chronic Lymphocytic Leukaemia

1981

View full text Add to dashboard Cite

show abstract

“…Since cutaneous Sezary cells have also been shown to have a low level of proliferation (Shackney et al, 1979), it would appear that the neoplastic cells of CTCL arise in some other site and migrate via the peripheral blood to the skin. Because of the small number of patients, sufficient data is not yet available to correlate the degree of spontaneous proliferation with the rate of disease progression, response to therapy and survival, as has been described for other myeloproliferative disorders (Moayeri and Sokal, 1979). Spontaneous transformation of cells from normal individuals occurring over the first ten days of culture has been shown to represent, at least in part, an autologous mixed leukocyte response of T-cell to non T cells (Kuntz et al, 1976).…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte transformation in patients with cutaneous T‐cell lymphomas

Carney

Bunn

Schechter

et al. 1980

Intl Journal of Cancer

View full text Add to dashboard Cite

The proliferative responses of peripheral blood mononuclear cells from ten patients with cutaneous T-cell lymphoma were tested after stimulation with a variety of mitogens, including phytohemagglutinin (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), staphylococcal protein A (SPA), and lymphocyte-conditioned medium (LyCM). Responses were measured by the incorporation of tritiated thymidine and by flow microfluorometry (FMF). In general, responses were depressed, although a broad range of responses were observed ranging from very poor to near normal responses. SPA and PWM were the most potent mitogens in the CTCL patients, unlike controls in whom PHA and SPA were the optimum mitogens and PWM was weakly mitogenic. FMF studies in two patients clearly demonstrated that aneuploid Sezary cells and not admixed normal lymphocytes were proliferating in response to SPA and PWM stimulation. The unusual pattern of mitogen responses found in these CTCL patients suggests Sezary cells may be derived from T-cell subpopulations with special affinity for SPA and PWM. The ability of FMF to demonstrate that aneuploid cells respond to mitogen stimulation makes it a useful additional technique in the evaluation of lymphocyte blastogenesis in patients with malignant lymphoproliferative disorders.

show abstract

“…A number of studies have attempted to correlate the survival of CLL patients with the biolog ic properties of CLL cells [8][9][10][11]. A number of studies [6,7] have confirmed the utility of the Rai staging system with respect to survival.…”

Section: Introductionmentioning

confidence: 99%

Combination Chemotherapy with the M-2 Protocol (BCNU, Cyclophosphamide, Vincristine, Melphalan, and Prednisone) for Chronic Lymphocytic Leukemia (Stages III and IV)

Case¹,

Porensky²,

Fanning³

1985

Oncology

View full text Add to dashboard Cite

The M-2 protocol was administered every 5 weeks to 25 patients with stage IIIand IV chronic lymphocytic leukemia (CLL). Complete remission (CR; absence of all clinical and bone marrow evidence of leukemia including normal immune markers for monoclonal disease) and partial remission (PR; >50% decrease in organ enlargement and reduction of WBC count to below 15,000 × 10⁶/1) were achieved in 20 and 48%, respectively. A median number of 24 cycles of therapy was required to produce a CR. The median duration of unmaintained remission was 12 months. All CR patients are still surviving. The median survival of the PR patients and the overall groups is 21 months. To improve the CR rate and survival in patients with advanced CLL, more effective methods of determining residual leukemic cells and different treatment strategies will be needed.

show abstract

In vitro leukocyte thymidine uptake and prognosis in chronic lymphocytic leukemia

Cited by 25 publications

References 8 publications

Thymidine Kinase Isoenzymes in Chronic Lymphocytic Leukaemia

Thymidine Kinase Isoenzymes in Chronic Lymphocytic Leukaemia

Lymphocyte transformation in patients with cutaneous T‐cell lymphomas

Combination Chemotherapy with the M-2 Protocol (BCNU, Cyclophosphamide, Vincristine, Melphalan, and Prednisone) for Chronic Lymphocytic Leukemia (Stages III and IV)

Contact Info

Product

Resources

About